Skip to main content
Premium Trial:

Request an Annual Quote

Bioneer Wins Grant to Develop RNAi Drug for Dengue Fever

Premium

NEW YORK (GenomeWeb) – South Korea's Bioneer announced that it has received a two-year, $1.3 million grant from the Korea Health Industry Development Institute to develop an siRNA-based therapy for dengue fever.

The therapeutic is based on Bioneer's so-called self-assembled micelle inhibitory RNA, or SAMiRNA, nanoparticle technology, and incorporates siRNAs targeting the dengue virus genome.

According to the company, it has received $500,000 of the award to conduct in vivo testing of its drug in a mouse model of dengue virus infection, which will be run in collaboration with the La Jolla Institute for Allergy and Immunology.

Upon successful completion of this first stage of the project, Bioneer is eligible to receive the remaining $800,000 in 2015.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.